| CASE REPORT |
|
| Year : 2014 | Volume
: 20
| Issue : 2 | Page : 187-188 |
|
|
Fetal valproate syndrome
Parmarth G Chandane, Ira Shah
Department of Pediatrics, Bai Jerbai Wadia Hospital for Children, Parel, Mumbai, Maharashtra, India
Correspondence Address:
Parmarth G Chandane
Department of Pediatrics, Bai Jerbai Wadia Hospital for Children, Parel, Mumbai - 400 014, Maharashtra
India
 Source of Support: None, Conflict of Interest: None  | 2 |
DOI: 10.4103/0971-6866.142898
|
|
|
Antenatal use of anticonvulsant valproic acid can result in a well-recognized cluster of facial dysmorphism, congenital anomalies and neurodevelopmental retardation. In this report, we describe a case with typical features of fetal valproate syndrome (FVS). A 26-year-old female with epilepsy controlled on sodium valproate 800 mg/day since 3 years, gave birth to a male child with characteristic features of FVS. She also had 3 spontaneous first-trimester abortions during those 3 years. Sodium valproate, a widely used anticonvulsant and mood regulator, is a well-recognized teratogen that can result in facial dysmorphism, craniosynostosis, neural tube defects, and neurodevelopmental retardation. Therefore, we strongly recommend avoidance of valproic acid and supplementation of folic acid during pregnancy. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
